SEC I	Form	4
-------	------	---

Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287

	0200 0201
Estimated average b	urden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Jerel Davis			2. Issuer Name and Ticker or Trading Symbol <u>CHINOOK THERAPEUTICS, INC.</u> [KDNY]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify						
(Last) C/O CHINOC	(First) OK THERAPE	(Middle) UTICS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 04/17/2023	below) below)						
1600 FAIRVIEW AVE. E., SUITE 100			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
				X Form filed by One Reporting Person						
(Street) SEATTLE	A8	98102		Form filed by More than One Reporting Person						
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication							
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Disposed Of	Acquire (D) (Inst	d (A) or r. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	04/17/2023		S ⁽¹⁾		295,808	D	\$ 20.7507 ⁽²⁾	443,713	D	
Common Stock								2,105,107	Ι	See Footnote ⁽³⁾
Common Stock								719,104	Ι	See Footnote ⁽⁴⁾
Common Stock								210,996	Ι	See Footnote ⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned pute calle war -----

	(e.g., puts, cans, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Pursuant to an arrangement between the Reporting Person and Versant Venture Management, LLC ("VVM"), the sale of these securities was executed by VVM on behalf of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$20.75 to \$20.97, inclusive. The Reporting Person and VVM undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein.

4. These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and the Reporting Person disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. 5. These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP-GP, Versant Ventures VI GP-GP, Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and the Reporting Person disclaims beneficial ownership of the versant Venture VI BP-Versant Venture VI BP-Versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Reporting Person disclaims beneficial ownership of the versant Ventures VI GP-GP and the Repor

shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein.

Remarks:

/s/ Max Eisenberg, Attorney-04/19/2023

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.